Most Clicked StoriesMore >


Hepatitis drug's pricing is target of class-action lawsuit

PCMA SmartBrief | Dec 11, 2014

A class-action lawsuit was filed Tuesday in federal court by the Southeastern Pennsylvania Transportation Authority over Gilead Sciences' pricing of its hepatitis C treatment Sovaldi. The suit claims that Gilead violated federal antitrust laws and abused its patent monopoly, and says the drug's pricing is discriminatory because some buyers receive discounts. Wall Street Journal (tiered subscription model), The (12/10) Reuters (12/10)


CMS to discuss pharmacy access study findings

PCMA SmartBrief | Dec 15, 2014

PCMA questions whether CMS study is prelude to interfering in pharmacy contracts

PCMA SmartBrief | Dec 17, 2014

Ohio pharmacy owner indicted on health care fraud charges

PCMA SmartBrief | Dec 12, 2014

FDA policies that boost competition would lower drug prices

PCMA SmartBrief | Dec 16, 2014

Consultants predict strong health plan enrollment

PCMA SmartBrief | Dec 12, 2014

Report: Global drug sales may fall $65 billion by 2019

PCMA SmartBrief | Dec 15, 2014

White paper: FDA's impact on competition in the drug industry

PCMA SmartBrief | Dec 16, 2014

Corporations approach private insurance exchanges with caution

PCMA SmartBrief | Dec 16, 2014

Anonymous matchback allows marketers to use prescription records

PCMA SmartBrief | Dec 12, 2014


Find PCMA SmartBrief Issues by Date:





Sign up for PCMA SmartBrief



Designed specifically for PBM industry professionals, PCMA SmartBrief is a FREE, daily e-mail newsletter. It provides the the most relevant and actionable PBM industry news in a quick, easy to read format. Learn more